Global Spine was Orthofix Medical’s largest segment in fiscal 2025, bringing in $687.66M of $822.31M (84%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Spine | $353.17M | $631.32M | $675.31M | $687.66M | |||||||||||||
| Spine Reporting | — | — | — | — | |||||||||||||
| Bone Growth Therapies | — | — | — | — | |||||||||||||
| Spine Regenerative Stimulation | — | — | — | — | |||||||||||||
| Biostim | — | — | — | — | |||||||||||||
| Orthopedics | — | — | — | — | |||||||||||||
| Orthopedics Reporting | — | — | — | — | |||||||||||||
| Spine Repair Implants & Regenerative Biologics | — | — | — | — | |||||||||||||
| Global Limb Reconstruction | — | $115.32M | $124.18M | $134.66M | |||||||||||||
| Sports Medicine Reporting | — | — | — | — | |||||||||||||
| Extremity Fixation | — | — | — | — | |||||||||||||
| Global Extremities | — | — | — | — | |||||||||||||
| Orthofix Extremities | — | — | — | — | |||||||||||||
| Global Orthopedics | $107.54M | — | — | — | |||||||||||||
| Spine Fixation | — | — | — | — | |||||||||||||
| Spinal Implants | — | — | — | — | |||||||||||||
| Biologics | — | — | — | — | |||||||||||||
| Total | $460.71M | $746.64M | $799.49M | $822.31M |
Orthofix Medical brought in $822.31M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 2.9% from $799.49M in fiscal 2024. Global Spine was the largest at $687.66M (83.6%), ahead of Global Limb Reconstruction at $134.66M (16.4%).
Compared with fiscal 2024, Global Limb Reconstruction grew 8.4% to $134.66M and Global Spine grew 1.8% to $687.66M.
Orthofix Medical began breaking out Global Limb Reconstruction in fiscal 2023, when it brought in $115.32M. Orthofix Medical stopped reporting Global Orthopedics as a separate segment after fiscal 2022, when it brought in $107.54M.
U.S was Orthofix Medical’s largest region in fiscal 2025, bringing in $684.07M of $822.31M (83%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $358.84M | $620.83M | $672.82M | $684.07M | ||||||||||||
| Others | $44.99M | $65.83M | $66.40M | $76.73M | ||||||||||||
| Italy | $19.10M | $20.06M | $21.00M | $22.28M | ||||||||||||
| Brazil | $5.67M | $6.45M | $5.71M | $4.84M | ||||||||||||
| France | $10.38M | $11.10M | $13.39M | $11.96M | ||||||||||||
| Germany | $11.57M | $11.47M | $9.00M | $9.11M | ||||||||||||
| United Kingdom | $10.17M | $10.91M | $11.18M | $13.33M | ||||||||||||
| U.K | — | — | — | — | ||||||||||||
| Total | $460.71M | $746.64M | $799.49M | $822.31M |
Orthofix Medical brought in $822.31M from its seven regions in fiscal 2025, the year ended December 31, 2025. That was up 2.9% from $799.49M in fiscal 2024. U.S was the largest at $684.07M (83.2%), ahead of Others at $76.73M (9.3%) and Italy at $22.28M (2.7%). The other four regions brought in $39.24M combined.
Compared with fiscal 2024, Others grew fastest, up 15.6% to $76.73M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $460.71M to $822.31M, a compound annual growth rate of 21.3%. U.S's share of the total rose from 77.9% to 83.2%.
Domestic Tax Authority was Orthofix Medical’s largest revenue line in fiscal 2017, bringing in $345.15M of $433.82M (80%).
| Income Tax Authority | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|
| Domestic Tax Authority | $294.68M | $305.51M | $316.87M | $345.15M | |||
| Foreign Tax Authority | $107.60M | $90.98M | $92.92M | $88.68M | |||
| Total | $402.28M | $396.49M | $409.79M | $433.82M |
Orthofix Medical brought in $433.82M from its two revenue lines in fiscal 2017, the year ended December 31, 2017. That was up 5.9% from $409.79M in fiscal 2016. Domestic Tax Authority was the largest at $345.15M (79.6%), ahead of Foreign Tax Authority at $88.68M (20.4%).
Compared with fiscal 2016, Domestic Tax Authority grew 8.9% to $345.15M, while Foreign Tax Authority fell 4.6% to $88.68M. From fiscal 2014 to 2017, combined revenue from these revenue lines grew from $402.28M to $433.82M, a compound annual growth rate of 2.5%. Domestic Tax Authority's share of the total rose from 73.3% to 79.6%.
Orthofix Medical (OFIX) reports its revenue by segment, by geography and by income tax authority. In fiscal 2025, Global Spine was its largest segment, bringing in $687.66M (83.6% of the total), followed by Global Limb Reconstruction at $134.66M (16.4%).
Global Spine was Orthofix Medical's largest segment in fiscal 2025, bringing in $687.66M, or 83.6% of the $822.31M total across its two segments.
U.S was Orthofix Medical's largest region in fiscal 2025, bringing in $684.07M, or 83.2% of the $822.31M total across its seven regions.
Domestic Tax Authority was Orthofix Medical's largest revenue line in fiscal 2017, bringing in $345.15M, or 79.6% of the $433.82M total across its two revenue lines.
Global Limb Reconstruction grew faster than Global Spine in fiscal 2025, up 8.4% from $124.18M to $134.66M. Global Spine grew 1.8% to $687.66M.
Every figure comes from Orthofix Medical's annual financial filings, as reported. Each line keeps the name Orthofix Medical gives it, and years follow its fiscal calendar.
Orthofix Medical's revenue by segment goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.